AngioDynamics, Inc. (NASDAQ:ANGO) stock rose 5.64% (As on July 13, 12:57:49 AM UTC-4, Source: Google Finance) after the company beaten the topline estimates for the fourth quarter of FY 22. Med Tech net sales were $22.6 million, a 40.0% increase from $16.2 million in the prior- year period, while Med Device net sales were $64.4 million, an increase of 6.1% compared to $60.7 million in the prior-year period. Med Tech includes the Auryon Peripheral Atherectomy platform, the thrombectomy platform and the NanoKnife irreversible electroporation platform. Endovascular Therapies (formerly Vascular Interventions and Therapies) net sales were $45.1 million, an increase of 18.5%, compared to $38.1 million a year ago. Growth was driven by Auryon sales during the quarter of $9.6 million, continuing the sequential growth trend in the business as well as strength in the Company’s thrombectomy portfolio as compared to the prior year. Oncology net sales were $15.1 million, an increase of 5.8%, compared to $14.3 million in the prior-year period. The year-over-year growth was largely due to increased net sales of disposables of NanoKnife and Microwave. Vascular Access net sales were $26.7 million, an increase of 9.3%, compared to $24.5 million a year ago. U.S. net sales in the fourth quarter of fiscal 2022 were $73.7 million, an increase of 15.9% from $63.6 million a year ago. International net sales were $13.3 million, an increase of 0.4%, compared to $13.2 million a year ago.

ANGO in the fourth quarter of FY 22 has reported the adjusted earnings per share of 1 cents, which is inline with the analysts’ estimates for the adjusted earnings per share of 1 cents, according to Zacks Investment Research. The company had reported the adjusted revenue growth of 13.2 percent to $87 million in the fourth quarter of FY 22, beating the analysts’ estimates for revenue of $82.6 million. The adjusted net income for the fourth quarter of fiscal 2022 was $0.3 million, compared to adjusted net loss in the prior-year period of $0.1 million. At May 31, 2022, the Company had $28.8 million in cash and cash equivalents compared to $23.9 million in cash and cash equivalents at February 28, 2022. The Company had $25.0 million outstanding under its revolving credit facility at May 31, 2022 which was in line with February 28, 2022.

AngioDynamics expects full-year earnings to be in the range of 1 cent to 6 cents per share, with revenue expected to be in the range of $342 million to $348 million.